Expand SPRY Menu
SPRY MENU

SPRY Latest Press Releases

-- March 27, 2026 --

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg (epinephrine nasal spray) Label Globe Newswire 8:00 AM

-- March 9, 2026 --

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization Globe Newswire 6:00 AM

-- February 23, 2026 --

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences Globe Newswire 8:00 AM

-- February 10, 2026 --

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting Globe Newswire 8:00 AM

-- February 2, 2026 --

EURneffy 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing =15 kg to <30 kg Globe Newswire 8:00 AM

-- January 21, 2026 --

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use Globe Newswire 8:00 AM

-- December 29, 2025 --

neffy (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) Globe Newswire 8:00 AM

-- November 26, 2025 --

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes